OUR STORY

The emergence of new infectious diseases, the re-emergence of “old” infectious diseases, the rise of antibacterial resistance and the difficulty to come out with a new pipeline of new antimicrobial compounds leads to consider the potential of non-conventional approaches, such as immunotherapies as new therapies.

Already on the fifth edition, the I4ID congress started on 2017 and the aim was to develop an exclusive conference dedicated to immunotherapies and infectious diseases, something that never existed before. In 2019, The thematic was enlarged to include, with the immunotherapies, all the innovations being developed to fight infectious diseases. Last year, regarding the unique sanitary situation we were going through, we had decided it was imperative to include on this edition program the COVID-19 thematic.

I4ID is co-organized by MabDesign, the association who the aim is to support and federate the french industrial sector of biotherapy (www.mabdesign.fr) and Lyonbiopôle, the healthcare cluster of the Auvergne-Rhône-Alpes region (https://lyonbiopole.com). These two emblematic health stakeholders have brought together, for two days, experts from around the world to combine approaches and strengths to innovate in the fields of infectious diseases and immunotherapy.

Previous topics addressed:
2017: Monoclonal Antibodies to fight infectious diseases
2018: Host-Directed Therapies (HDT)
2019: Immunotherapies & Innovations to fight infectious diseases
2020: COVID-19 outbreak
2021: New trends following the COVID-19 outbreak

KEY FIGURES

- 1000+ Attendees
- 180+ High-profile speakers
- 390+ Different organizations present
- 740+ B2B meetings
The **I4ID2022** program included 5 tracks with keynote lectures, parallel plenary sessions, pitch talks and industrial talks covering the latest developments and highest innovative projects in the field. Furthermore, it was possible to set up, through an online platform, business meetings during both days (partnering).

The topics covered during this congress were:
- Alternative to antibiotics and current antivirals
- New advancements in Immunotherapies
- Innovative vaccines
- Diagnostic, prognostic and clinical biomarkers
- Fostering infectious diseases public-private initiatives
WHO ATTENDED IN 2022?

KEY FIGURES

✓ 250+ participants from different countries
✓ 110+ different organizations present
✓ 240+ BtoB meetings took place
✓ 44 High-profile Speakers
✓ 26 Sponsors & Exhibitors

WHERE FROM?

- 90% Northern Europe
- 6% Western Europe
- 1% Eastern Europe
- 1% Southern Europe
- 2% North, America
- 1% Other

COMPANY TYPE
- START-UP
- MATURER COMPANY
- BIOTECH - SME
- ACADEMIC & CLINICIAN
- CLUSTER & CONSULTANT
- OTHER

JOB TITLE
- STRATEGY & LEADERSHIP: 54%
- BUSINESS DEVELOPMENT: 18%
- RESEARCH: 22%
- OTHER: 5%
WHO ATTENDED IN 2022?

COMPANIES WHICH ATTENDED:

Day 1 | Wednesday 23rd November 2022

08.30
Registration & welcome coffee

09.15
Welcome Address

09.30
OPENING KEYNOTE – CHARLES MÉRIEUX AUDITORIUM

Harnessing mRNA’s Power: going from one success today to tomorrow full potential
Régis Gervier I Global Head of mRNA Center of Excellence | Sanofi, France

10.00
Coffee Break - B2B Meetings – EXHIBITION HALL

10.30
TRACK 1: ALTERNATIVE TO ANTIBIOTICS AND CURRENT ANTIVIRALS
CHARLES MÉRIEUX AUDITORIUM
Session 1

Regulatory hurdles while developing a phage cocktail for Ventilator-Associated Pneumonia in Europe

Sofia Côrte Real I Scientific advisor | TechnoPhage, Portugal

Immune modulation of microbiome: host interactions in acne vulgaris
Sanja Selak I Managing director and CSO | ORIGIMM Biotechnology, Austria

Scalable antibiotic discovery through synthetic biology
Vincent Libis I Research Group Leader | INSERM, France

TRACK 2: NEW ADVANCEMENTS IN IMMUNOTHERAPIES
THESIS ROOM
Session 1

Antipseudomonal monoclonals
Jean Chastre I PU-PH | APHP, France

Leveraging continuous manufacturing to expand global access to biotherapeutics
Christelle Dagoneau I Senior Vice Presidente, Global Business Development | Just-Evotec Biologics, France

Monoclonal antibodies as immunization: innovation in RSV for all infant protection
Kocfa Chung I Global Medical Expert, Strategy Lead RSV Global Medical Franchise | Sanofi, France
AGENDA 2022

12.00  Lunch - B2B Meetings 2 slots – EXHIBITION HALL

13.00  Poster Presentation - B2B Meetings 3 slots – EXHIBITION HALL

14.00  TRACK 3: FOSTERING INFECTIOUS DISEASES PUBLIC-PRIVATE INITIATIVES – CHARLES MÉRIEUX AUDITORIUM
       Session 1

       A new agency: ANRS-MIE, Moving to Emerging Infectious diseases.
       Hervé Raoul | Directeur adjoint | ANRS, France

       HUB VPH: an international hub devoted to veterinary public health
       Régis Villet | Strategic Partnership Manager | Bioaster, France

14.30  TRACK 2: NEW ADVANCEMENTS IN IMMUNOTHERAPIES
       THESIS ROOM
       Session 2

       Advances in immune adjuvant therapy in critically ill patients
       Anne-Claire Lukaszewicz | Head of Department | Hospices Civils de Lyon, France

       Title to be announced
       Hasan Jafri | Chief Medical Officer | Aridis Pharmaceuticals, USA

15.30  TRACK 1: ALTERNATIVE TO ANTIBIOTICS AND CURRENT ANTIVIRALS
       CHARLES MÉRIEUX AUDITORIUM
       Session 2

       Dynamic Computational Models of Bacteria: From Target-Identification to Drugs
       Ed Siegwart | Director of Microbiology | Oppiotech, United Kingdom

       Machine learning for antibiotic discovery against Acinetobacter baumannii
       Jon Stokes | Assistant Professor | Stokes Laboratory / McMaster University, Canada

       BREAKTHROUGH INNOVATION
       THESIS ROOM
       Session 1

       Respiratory Syndrome: Multiplex PCR test for viral straightforward characterization and monitoring of pandemic risks
       Laëtitia Villiers | R&D project manager | AXO Science, France

       Effective in vivo protection of the broad neutralizing antibody 10-1074 against mucosal cell-associated SHIV infection in non-human primates
       Mariangela Cavarelli | Researcher | CEA, France

15.30  Coffee Break - B2B Meetings 3 slots – EXHIBITION HALL
16.00

**TRACK 1: ALTERNATIVE TO ANTIBIOTICS AND CURRENT ANTIVIRALS**

**CHARLES MÉNEUX**

**AUDITORIUM**

**Session 3**

*The central role of diagnostics in personalized phage therapy and our rapid automated phagogram*

**Bob Blasdel | Research Director | Vésale Bioscience, Belgique**

*Alternative approach to discover small molecule antibiotics*^*^*

**Sébastien Coyne | Project and Team Leader in Bacteriology Omics Platform | Evotec, France**

*Generation of functional monoclonal antibodies by different platforms for antiviral research and immunotherapy*^*^*

**Yu-Chih Lin | Technical Specialist | Sino Biological, Germany**

*New psVLP neutralization assay using bio luminescence: Proof of Concept on SARS-CoV-2*

**Florian Mignot | Cell-based assays specialist | Promega, France**

*Multi-modal immune profiling at single cell resolution*^*^*

**Koen De Geus | Science and Technology Advisor | 10x Genomics, USA**

**BREAKTHROUGH INNOVATION SESSION**

**THEBIS ROOM**

**Session 2**

*Multi-omics longitudinal analysis as a new deep characterization tool for bacterial fermentation optimization*

**Charlotte Mignon | Research Scientist | Bioaster, France**

*Respiratory Syndrome: Multiplex PCR test for viral straightforward characterization and monitoring of pandemic risks*

**Marianne Figl | Study Director | Virocan, France**

*Intracellular Staphylococcus aureus replicative dynamics monitoring under antibiotics challenges: highlighting persisters*

**Florian C. Marro | PhD Student | Evotec ID, France**

*Microalgae Extracellular Vesicles: an effective delivery system for human therapeutics and vaccines*

**Manuel Vega | CED | AGIS Therapeutics, France**

17.10

**End of DAY 1**

19.00

**Cocktail Diner at Musée des Confluences**
Welcome coffee

OPENING – CHARLES MÉRIEUX AUDITORIUM

Title to be announced
Fabio Bagnoli | Senior Scientific Director | GlaxoSmithKline, Italy

A bird’s eye view of SARS-CoV2 vaccines: from vaccine immunology to vaccine effectiveness
Robbert Van Der Most | Vice President Translational Science | BioNTech, Germany

Coffee Break - B2B Meetings – EXHIBITION HALL

10.30

TRACK 4: INNOVATIVE VACCINES
CHARLES MÉRIEUX AUDITORIUM
Session 1

Long-lasting effects of vaccination on innate myeloid cells
Anne-Sophie Beignon | Researcher | Inserm, CEA, IMVA-HB/IDMIT, France

A nasal vaccine to end the COVID-19 pandemic?
Isabelle Dimier-Poisson | CSO | LoValTech | France
Patrick Barillot | CEO | LoValTech, France

Transboundary and Emerging Diseases: Getting ready
Jeroen Kortekaas | Scientific Director, Transboundary and Emerging Diseases | Boehringer Ingelheim, France

Immunotherapies for infectious diseases
Pedro Madureira | Co-founder and CSO | Immunethep, Portugal

TRACK 5: DIAGNOSTIC, PROGNOSTIC AND CLINICAL BIOMARKERS
THESIS ROOM

Targeting TREM-1 to Manage Life-threatening Immune Disorders Caused by Severe Infections - Application in Septic Shock and COVID-19 (Title to be confirmed)
Margarita Salcedo Maggull | Chief Development Officer | Inotrem, France

Sepsis-associated immunosuppression: diagnostic issues
Louis Kreitmann | Researcher | bioMérieux, France

BREAKTHROUGH INNOVATION SESSION
THESIS ROOM
Session 3

Identification of a neutralizing antibody targeting, vaccinia virus, variola virus and the current strain of pandemic monkeypoxvirus
Arnaud Avril | Deputy director of the Microbiology and Infectious Diseases Department | IRBA, Ministère des Armées, France
Ensuring clinical availability of vaccine delivery systems, immunostimulators and combined adjuvant systems beyond COVID-19
Dennis Christensen I Head of Global Research and Development, Adjuvant Systems | Croda Pharma, Denmark

SEPSI-SCORE: Presentation of a Sepsis risk prediction AI solution
Quentin François I CEO | PREVIA MEDICAL, France

System’s biology acting alternatives to antibiotics and current antivirals obtained by Artificial Intelligence, naturally
Pascal Mayer I CEO | Alphanosos, France

12.30 Lunch - B2B Meetings 2 slots – EXHIBITION HALL

13.30 Poster Presentation - B2B Meetings 3 slots – EXHIBITION HALL

14.30 TRACK 3: FOSTERING INFECTIOUS DISEASES PUBLIC-PRIVATE INITIATIVES – CHARLES MÉRIEUX AUDITORIUM Session 2

Fostering infectious diseases public private initiative in the field of antimicrobial resistance
François Lacoste I Executive Vice President, Research & Development | bioMérieux, France | Comité stratégique de filière (CSF) Antibiorésistance, France

Advances of the National Acceleration Strategy for Emerging Infectious Diseases and CBRN threats – France 2030
Nadia Khelef I Coordinator | National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats, France

What pull incentives adapted to SMEs to restore the business model of antibiotics
Florence Séjourné I Founder and Board Member | BEAM Alliance & CEO - Aurobac Therapeutics, France

15.00 TRACK 4: INNOVATIVE VACCINES – CHARLES MÉRIEUX AUDITORIUM Session 2

MOPEVAC, a vaccine platform against all pathogenic Arenaviruses
Sylvain Baize I PI | Pasteur Institute - France

Protective secretory IgA response by repertoire amplification
Fabio Grassi I Chairman | MIV BioTherapeutics, Switzerland

Engineering Bioconjugation Platform for Vaccines Development
Sherif Abouelhadid I Head at Biological and Pharmacological Pillar at: Antimicrobial Resistance Centre | London school of Hygiene & Tropical Medicine, United Kingdom

16.30 Best Poster - Announcement of next year edition

17.00 End of congress
SCIENTIFIC ADVISORY BOARD

Bruno François
Specialist in Intensive Care medicine and Anesthesiology
University Hospital of Limoges

Geneviève Inchauspé
Senior Director, Head of the Department of Infectious Diseases
Transgene

Sandra Morel
Director, Research Project Leader, Discovery Performance Unit
GSK Vaccines

Pr. Bruno Lina
University Professor and Hospital Practitioner, Director National Reference Center for respiratory infections virus, VirPath Laboratory, University Lyon 1

Cyril Guyard
Deputy CSO
Bioaster

Sébastien Coyne
Project and Team Leader in Bacteriology Omics Platform
Evotec

Daniel Larocque
Microbiology-Immunology Platform Manager
Sanofi

Michel Perez
Head of Development Of Innovation Department Pasteur Institute

Karin Loré
Professor Institut Karolinska

Jenny Hendriks
Head Biomarkers Viral Vaccines
Janssen Vaccines
SCIENTIFIC ADVISORY BOARD

Jean François Llitjos
Scientific and medical
Expert Open innovation
and Partnership
bioMérieux

Gokul Swaminathan
Director, Innovation in Vaccinology
Boehringer Ingelheim

Yazdan Yazdanpanah
Director
ANRS | Maladies infectieuses émergentes

Thierry Walzer
DR Team Leader
CIRI

Fabienne Venet
University professor, Hospital practitioner
Hospices Civils de Lyon

Evelyne Jouvin Marche
Director
Fondation Finovi

Laure Delhon
Events Manager and Communication
MabDesign

Natalia Bomchil
Innovation Director
Lyonbiopole
2022 SPONSORS

Gold Sponsors

Boehringer Ingelheim  sanofi

Bronze Sponsors

10X GENOMICS  CRODA

evotec  GSK

Promega  Sino Biological
2022 EXHIBITORS
2022 PARTNERS

Contributing partner

IDT
INTEGRATED DNA TECHNOLOGIES

Supporting partners

ANRS
La Région
Auvergne-Rhône-Alpes
MÉTROPOLE
GRAND LYON

Institutional and Media partners

Inserm
La gazette du LABORATOIRE
November 2023 – LYON, FRANCE

For more information, Please contact Laure Delhon – MabDesign at: laure.delhon@mabdesign.fr or tel. 0033 (0)4 78 02 39 89

Follow Us

#I4ID2023